266 related articles for article (PubMed ID: 26827834)
1. Cancer immunology and canine malignant melanoma: A comparative review.
Atherton MJ; Morris JS; McDermott MR; Lichty BD
Vet Immunol Immunopathol; 2016 Jan; 169():15-26. PubMed ID: 26827834
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen.
Gyorffy S; Rodriguez-Lecompte JC; Woods JP; Foley R; Kruth S; Liaw PC; Gauldie J
J Vet Intern Med; 2005; 19(1):56-63. PubMed ID: 15715049
[TBL] [Abstract][Full Text] [Related]
3. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T
Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170
[TBL] [Abstract][Full Text] [Related]
4. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.
von Euler H; Sadeghi A; Carlsson B; Rivera P; Loskog A; Segall T; Korsgren O; Tötterman TH
J Immunother; 2008 May; 31(4):377-84. PubMed ID: 18391758
[TBL] [Abstract][Full Text] [Related]
5. Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells.
Tamura K; Yamada M; Isotani M; Arai H; Yagihara H; Ono K; Washizu T; Bonkobara M
Vet J; 2008 Jan; 175(1):126-9. PubMed ID: 17208475
[TBL] [Abstract][Full Text] [Related]
6. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.
Bergman PJ; Camps-Palau MA; McKnight JA; Leibman NF; Craft DM; Leung C; Liao J; Riviere I; Sadelain M; Hohenhaus AE; Gregor P; Houghton AN; Perales MA; Wolchok JD
Vaccine; 2006 May; 24(21):4582-5. PubMed ID: 16188351
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
8. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
Riccardo F; Iussich S; Maniscalco L; Lorda Mayayo S; La Rosa G; Arigoni M; De Maria R; Gattino F; Lanzardo S; Lardone E; Martano M; Morello E; Prestigio S; Fiore A; Quaglino E; Zabarino S; Ferrone S; Buracco P; Cavallo F
Clin Cancer Res; 2014 Jul; 20(14):3753-62. PubMed ID: 24874834
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapies.
Bergman PJ
Vet Clin North Am Small Anim Pract; 2019 Sep; 49(5):881-902. PubMed ID: 31186125
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.
Grosenbaugh DA; Leard AT; Bergman PJ; Klein MK; Meleo K; Susaneck S; Hess PR; Jankowski MK; Jones PD; Leibman NF; Johnson MH; Kurzman ID; Wolchok JD
Am J Vet Res; 2011 Dec; 72(12):1631-8. PubMed ID: 22126691
[TBL] [Abstract][Full Text] [Related]
11. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma.
Treggiari E; Grant JP; North SM
J Vet Med Sci; 2016 Jun; 78(5):845-50. PubMed ID: 26781703
[TBL] [Abstract][Full Text] [Related]
12. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.
Piras LA; Riccardo F; Iussich S; Maniscalco L; Gattino F; Martano M; Morello E; Lorda Mayayo S; Rolih V; Garavaglia F; De Maria R; Lardone E; Collivignarelli F; Mignacca D; Giacobino D; Ferrone S; Cavallo F; Buracco P
Vet Comp Oncol; 2017 Sep; 15(3):996-1013. PubMed ID: 27146852
[TBL] [Abstract][Full Text] [Related]
13. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.
Manley CA; Leibman NF; Wolchok JD; Rivière IC; Bartido S; Craft DM; Bergman PJ
J Vet Intern Med; 2011; 25(1):94-9. PubMed ID: 21143299
[TBL] [Abstract][Full Text] [Related]
14. Generation of blood-derived dendritic cells in dogs with oral malignant melanoma.
Catchpole B; Stell AJ; Dobson JM
J Comp Pathol; 2002; 126(2-3):238-41. PubMed ID: 11945016
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma.
Ottnod JM; Smedley RC; Walshaw R; Hauptman JG; Kiupel M; Obradovich JE
Vet Comp Oncol; 2013 Sep; 11(3):219-29. PubMed ID: 23909996
[TBL] [Abstract][Full Text] [Related]
16. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
17. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
Bergman PJ; McKnight J; Novosad A; Charney S; Farrelly J; Craft D; Wulderk M; Jeffers Y; Sadelain M; Hohenhaus AE; Segal N; Gregor P; Engelhorn M; Riviere I; Houghton AN; Wolchok JD
Clin Cancer Res; 2003 Apr; 9(4):1284-90. PubMed ID: 12684396
[TBL] [Abstract][Full Text] [Related]
19. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
20. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.
Alexander AN; Huelsmeyer MK; Mitzey A; Dubielzig RR; Kurzman ID; Macewen EG; Vail DM
Cancer Immunol Immunother; 2006 Apr; 55(4):433-42. PubMed ID: 15965647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
